ICLR250117P175000
- 7.30
- 0.000.00%
Icon PLC Newsroom
Express News | ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer's and Related Disorders ICON Survey
ICON Plc Draws Bullish Views at RBC on Attractive Valuation
Express News | Icon Shares Are Trading Higher After RBC Capital Initiated Coverage on the Stock With an Outperform Rating and Announced a Price Target of $263
ICON Up Over 5%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Icon Initiated at Outperform by RBC Capital
Icon Price Target Announced at $263.00/Share by RBC Capital
ICON Plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RBC Capital Initiates Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $263
Icon Price Target Cut to $290.00/Share From $300.00 by Citigroup
Icon Is Maintained at Buy by Citigroup
Citi Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $290
Express News | ICON PLC : Citigroup Cuts Target Price to $290 From $300
Does ICON (NASDAQ:ICLR) Have A Healthy Balance Sheet?
ICON Public Limited Company (ICLR) Slid on Drop in Biotechnology Funding
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $260
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
Icon Analyst Ratings
Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?